[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Arkansas, Fayetteville\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":198},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,74,105,127,151,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100524966","phase-2-the-effects-of-cannabigerol-on-attention-deficithyperactivity-disorder-100524966",false,"NCT06115603","The Effects of Cannabigerol on Attention-Deficit\u002FHyperactivity Disorder","CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit\u002FHyperactivity Disorder","CBG","1. Between 18 and 55-years-old.\n2. BMI between 18 and 35 kg\u002Fm2.\n3. Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.\n4. Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.\n5. Are not pregnant or currently breastfeeding.\n6. Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.\n7. Have not used CBG or any other cannabinoid products in the past 30 days.\n8. Willing to abstain from using cannabis or any THC-containing product for the duration of the study.\n9. Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).\n10. Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.\n11. Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.\n12. Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.\n13. Not currently having thoughts of committing suicide\n14. Does not meet criteria for current severe major depressive disorder or a substance use disorder.\n15. Have not been diagnosed with bipolar disorder or psychosis.\n16. Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).\n17. Do not have history of diagnosis related to liver function and\u002For significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).\n18. Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.\n19. Have access to a ride to the University of Arkansas campus for research appointments.\n20. Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).\n21. Do not have any serious or unstable physical health conditions including neurological or renal illness.\n22. Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.\n23. No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.\n24. No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.\n25. Not currently prescribed or taking the following medications:\n\n    * Warfarin\n    * Clobazam\n    * Valproic acid\n    * Phenobarbital\n    * Mechanistic Target of Rapamycin \\[mTOR\\] Inhibitors\n    * Oral tacrolimus\n    * St. John's wort\n    * Epidiolex\n    * Escitalopram\n    * Cardiovascular medications\n    * Strong CYP3A4 inhibitors (e.g., ketoconazole)",true,"ALL","18 Years","55 Years",{"count":22,"type":23},76,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit\u002FHyperactivity Disorder (ADHD) in a sample of participants indicating\u002Freporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.",[29],"Attention-Deficit\u002FHyperactivity Disorder","RECRUITING","2026-05-22",{"date":33,"type":34},"2026-05-27","ACTUAL",{"date":36,"type":34},"2024-12-14",{"date":38,"type":23},"2026-07",{"name":40,"class":41},"University of Arkansas, Fayetteville","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100628676","time-onset-sweat-sodium-toss-study-100628676","NCT07464743","Time Onset Sweat Sodium (TOSS) Study","TOSS","Inclusion Criteria:\n\n* Regular exercisers\n* Otherwise healthy individuals\n* Capable of running\u002Fjogging or cycling for 120min straight\n\nExclusion Criteria:\n\n* Heat illness in the past 3 years\n* Taking medications that alter fluid balance or Na retention\n* Chronic conditions that contraindicate long duration exercise in the heat","49 Years",{"count":52,"type":23},40,[54],"NA","Prior to each trial, you will be provided with urine jugs and food\u002Ffluid logs to record food and drink intake for 24hr. You will be asked to log food\u002Ffluid intake 24hr leading into trials. We ask that you match your diet for both trials, as much as possible. Also, we ask that you match caffeine consumption prior to trials. Lastly, we ask that you refrain from strenuous exercise and alcohol consumption for at least 12hrs leading into trials. Either of these exclude your participation in the study for safety reasons. You will be asked to provide a small urine sample upon arrival to the lab before trials. The purpose of this is to verify hydration prior to exercise in the heat. If you are not hydrated upon arrival, you will be provided and asked to drink 16oz (a bottle) of water prior to the trial. Just prior to, and following each long trial, you will be asked to provide a small saliva sample. To do this, you will be asked to actively produce saliva and guide it into a small container. This process takes \\\u003C5min. Next, you will have your nude body mass measured and you will be instrumented with a labbased sweat collection patch (large band-aid on the forearm), and the Hdrop sweat detection device on your left upper arm. The Hdrop will be synced with electronic applications (phone apps) to assure data collection. You will then self-insert a rectal thermistor \\~15 cm past the anal sphincter to monitor core temperature throughout exercise (for safety purposes). You will also be fitted with a heart rate strap that goes around your chest. You will then be asked to enter the environmental chamber and exercise for 30min. This will serve as the short exercise trial aiming to assure comfort with the 120min exercise trials. Data will be collected during the short trial and comparisons will be made for the longer, 120min trials. The environmental chamber will maintain a consistent temperature (80-100 degrees F) and humidity (40 to 60 % relative humidity). You will be monitored for safety throughout exercise in all 3 trials, and you will be allowed to cycle (stationary bike) or run or walk (treadmill) at your own pace\u002Fintensity. Pace and intensity will be recorded during the first trial and attempts will be made to match exercise intensity for subsequent trials. Fluid consumption will be allowed during trials and will be matched between trials. In both trials, you will be allowed to drink for a 5min period at each 30min interval (30-35min, 60-65min and 90-95min). We will provide a sport drink of your flavor choice during exercise.",[57,58,59],"Sweat Rate","Heat Effect","Sweat Sodium Concentration",[61,62,63,64],"Sweat rate","Exercise in the heat","Sweat sodium","Validity","NOT_YET_RECRUITING","2026-03-09",{"date":68,"type":34},"2026-03-11",{"date":70,"type":23},"2026-02-16",{"date":72,"type":23},"2026-08",{"name":40,"class":41},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100605146","protein-and-polycystic-ovary-syndrome-pcos-100605146","NCT07158723","Protein and Polycystic Ovary Syndrome (PCOS)","Assessing the Role of Higher Protein Diets in Managing Metabolic Complications of Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Females ages 18-50 years\n* Confirmed diagnosis of PCOS\n* Body mass index (BMI) between 18.5 and 35 kg\u002Fm2\n* Stable body weight for at least 3 months (+ 5 pounds)\n* Willingness to consume both plant- and animal-based protein meals\n\nExclusion Criteria:\n\n* Smoking or use of nicotine products\n* Smoking, vaping, and\u002For use of marijuana products\n* More than 4 alcoholic beverages per week\n* Food allergies or dietary restrictions incompatible with test meals\n* Diagnosed diabetes (type 1 or 2) or other preexisting chronic disease(s).\n* Use of medications that interfere with study outcomes (e.g., metformin, GLP-1 agonists, etc.)\n* Consumption of more than 0.8 g\u002Fprotein\u002Fkg body weight\n* Underweight\n* Taking nutritional supplements","FEMALE","50 Years",{"count":84,"type":23},60,[54],"Polycystic ovary syndrome (PCOS) is a significant public health problem and is one of the most common hormonal disturbances affecting women of reproductive age. Women with PCOS are often insulin resistant, increasing their risk for cardiometabolic health problems (e.g., type 2 diabetes, heart disease, high blood pressure, sleep apnea, anxiety, depression, and stroke) especially if they are overweight. Lifestyle modifications, including dietary changes and regular physical activity, may alleviate metabolic dysfunction in women with PCOS and are often the first line of management for patients with PCOS. Several studies have identified protein as a key nutrient for regulation of energy balance, maintenance of skeletal muscle mass, and improving cardiometabolic health across the lifespan. However, the effect of increased protein intake (30% of total energy intake) on cardiometabolic health in women with PCOS has not been well-defined and mechanisms for these effects have not been identified.\n\nThere is an evident need for well-designed, randomized controlled trials evaluating the efficacy of increased protein intake in women with PCOS on markers of cardiometabolic health. Preliminary data from collaborative projects with the investigators on this proposal suggest that increasing protein in the diet has the potential to improve markers of cardiometabolic health, potentially through improvements in body composition and\u002For changes in cortisol, energy metabolism, inflammation, and neurological regulators",[88],"Polycystic Ovary Syndrome (PCOS)",[90,91,92,93,94,95],"PCOS","polycystic ovary syndrome","protein","women","wellbeing","metabolism","2025-09-02",{"date":98,"type":34},"2025-09-08",{"date":100,"type":34},"2025-08-01",{"date":102,"type":23},"2027-12-03",{"name":40,"class":41},2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100603906","appetite-response-to-meals-with-different-protein-sources-in-women-with-pcos-100603906","NCT07142603","Appetite Response to Meals With Different Protein Sources in Women With PCOS","Comparative Meal Response to Plant vs. Animal Protein in Women With PCOS","Inclusion Criteria:\n\n* Females ages 18-50 years\n* Confirmed diagnosis of PCOS\n* Body mass index (BMI) between 18.5 and 35 kg\u002Fm2\n* Stable body weight for at least 3 months (+ 5 pounds)\n* Willingness to consume both plant- and animal-based protein meals\n\nExclusion Criteria:\n\n* Smoking or use of nicotine products\n* Smoking or use of marijuana products\n* Food allergies or dietary restrictions incompatible with test meals\n* Diagnosed diabetes (type 1 or 2)\n* Use of medications that interfere with study outcomes (e.g., metformin, GLP-1 agonists, etc.)",{"count":113,"type":23},30,[54],"Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that improve postprandial insulin and glucose responses are central to managing metabolic symptoms in PCOS.\n\nMeals higher in protein can attenuate postprandial glycemia and enhance satiety, but the effects may vary by protein source. Animal sources of protein typically have higher essential amino acid content and insulinogenic potential, whereas plant proteins offer fiber and phytochemicals that may influence glycemic dynamics differently. Few studies have directly compared the acute metabolic effects of plant versus animal protein in women with PCOS. Given the distinct pathophysiology of PCOS, extrapolating findings from healthy populations may be misleading.\n\nUnderstanding protein-specific effects on postprandial insulin, glucose, and appetite-regulating hormones in this group is essential for targeted nutrition guidance. Additionally, plant-based diets are increasingly promoted for cardiometabolic health, but their acute effects in insulin-resistant women remain underexplored. This study will assess whether plant and animal protein meals elicit differential postprandial responses in women with PCOS. Findings may inform dietary recommendations aimed at improving metabolic outcomes in this high-risk population.",[88],[90,91,118,119],"Protein","Women","2025-08-25",{"date":96,"type":34},{"date":123,"type":34},"2025-08-18",{"date":125,"type":23},"2027-06-30",{"name":40,"class":41},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":17,"sex":18,"minAge":135,"maxAge":82,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100435380","time-restricted-feeding-muscle-and-metabolism-100435380","NCT04949451","Time Restricted Feeding, Muscle, and Metabolism","Time Restricted Feeding Intervention for Muscle and Metabolic Health (TRIMM)","TRIMM","Inclusion Criteria:\n\n* Resides in Northwest Arkansas\n* Age 25-50 years\n* BMI \\> 25\n* All ethnicities\n* Female and male\n\nExclusion Criteria:\n\n* Food allergies\n* Pregnant or breastfeeding\n* Dietary restrictions (e.g. vegetarian, vegan, etc.)\n* Trying to lose weight in last 3 months\n* Pre-existing health conditions related to obesity (e.g. cardiovascular disease, diabetes, hypertension)\n* Prescription medications related to heart disease or type 2 diabetes\n* Fear of needles\n* Smoker or vaping\n* Currently taking protein supplements or other nutritional supplements which may interfere with study outcomes\n* Consumes \\>4 alcoholic beverages per week","25 Years",{"count":137,"type":23},90,[54],"Effective nutrition strategies for combatting and\u002For preventing obesity still need to be identified. This has been the case despite the numerous and different approaches that have been taken. Potential targets for combatting\u002Fpreventing obesity have been identified, but long-term solutions have not emerged. This study uses time restricted feeding to study the role of dietary protein in obesity prevention and\u002For treatment. The objectives are to determine the role of skeletal muscle mass as a driver of energy-sensing mechanisms and peripheral signals that regulate appetite and energy intake in overweight and obese adults and to determine the effects of protein timing on muscle mass to regulate appetite and energy intake in overweight and obese adults.",[141,142],"Overweight","Obesity","2025-08-19",{"date":145,"type":34},"2025-08-26",{"date":147,"type":34},"2021-06-13",{"date":149,"type":23},"2025-12-30",{"name":40,"class":41},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":42},"100559935","targeting-components-of-distress-tolerance-100559935","NCT06570603","Targeting Components of Distress Tolerance","Inclusion Criteria:\n\n* Fluent in English\n* Uses Android or iPhone smartphone\n* Depression Anxiety and Stress Scale (DASS-21) scores of 42 and higher\n* Distress Intolerance Index (DII) scores of 3 or higher\n\nExclusion Criteria:\n\n* Work or School that does not allow consistent access to phone (or is unsafe)\n* No internet access for completing follow-up surveys",{"count":158,"type":23},240,[54],"The goal of this clinical trial is to learn which aspects of distress intolerance (i.e., difficulties withstanding upsetting emotional states) are the most important for improving effective emotion regulation and associated mental health symptoms.\n\nThe main questions it aims to answer are:\n\nHow are willingness to feel upset and self-efficacy for withstanding distress associated with different emotion regulation strategies used in daily life?\n\nDoes targeting willingness to feel upset and\u002For self-efficacy for withstanding distress help people use more effective emotion regulation strategies in daily life when they feel upset?\n\nAre improvements in emotion regulation strategies in daily life associated with fewer symptoms of mental health problems over time?\n\nParticipants will:\n\nAnswer questions about their moods, willingness to feel upset, self-efficacy for withstanding distress and emotion regulation strategies for three weeks using a cell phone app\n\nUndergo a willingness, self-efficacy, combined or psychoeducational control intervention in the lab\n\nBe prompted to use the intervention skill via the cell phone app during the second week, after the intervention\n\nComplete weekly reports of mental health symptoms",[162],"Distress, Emotional","2025-07-07",{"date":165,"type":34},"2025-07-10",{"date":167,"type":34},"2024-10-03",{"date":169,"type":23},"2027-04",{"name":40,"class":41},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":81,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":104},"100581400","protein-and-exercise-for-postmenopausal-womens-wellbeing-100581400","NCT06849817","Protein and Exercise for Postmenopausal Women's Wellbeing","PRO-WELL: Protein and Exercise for Postmenopausal Women's Wellbeing","PROWELL","Inclusion Criteria:\n\n* Postmenopausal women aged 50 years and older (at least 12 months since last menstrual cycle)\n* Participant in physical activity (e.g., 2-4 bouts of physical activity per week (i.e., activities such as brisk walking, yoga, hiking, cycling, gardening, etc.)) -Participants taking hormone replacement therapy (HRT; at least 6 months on HRT), statins, and antihypertensive medications will be allowed to participate.\n\nExclusion Criteria:\n\n* Food allergies\n* Dietary restrictions (e.g., vegan, vegetarian, lactose intolerance, etc.)\n* Diet-related conditions that would prevent them from consuming a higher protein dietary intake (e.g., impaired liver function, kidney disease)\n* Participants consuming more than 0.8 g protein\u002Fkg\u002Fbody weight per day (determined by 24-hour dietary recall)\n* Underweight (BMI \\\u003C 18.5)\n* Taking nutritional supplements\n* Currently smoking or vaping\n* Use marijuana\n* Drink more than 4 alcoholic beverages a week\n* Take medications that may interfere with the primary outcomes of the dietary intervention (e.g., antidepressants, sleep medication, etc.)\n* Sleep apnea\n* Pittsburgh Sleep Quality Index (PSQI) global score \\>5 via or sleep \\> 7 hours a night\n* Pre-existing health conditions (e.g., diabetes (type I or II), cancer, Parkinson's Disease, Multiple Sclerosis) or conditions that would prevent them from fully participating in all aspects of the study.",{"count":137,"type":23},[54],"The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are:\n\n* Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women?\n* What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise?\n\nResearchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training.\n\nParticipants will:\n\n* Consume a higher protein diet for 16 weeks\n* Participate in an at-home resistance training for 16 weeks\n* Keep a diary of their food intake, sleep habits, and mood\n* Have health assessments every 4 weeks",[183],"Postmenopausal",[183,118,185,186,187,188,189],"Mood","Sleep","Wellbeing","Body composition","Amino acids","2025-02-24",{"date":192,"type":34},"2025-02-27",{"date":194,"type":34},"2024-10-01",{"date":196,"type":23},"2026-06-30",{"name":40,"class":41},""]